Background/Aims: H. pylon eradication has been recommended for dyspeptic patients in high prevalance regions. Triple therapies are still prescribed mostly because culture and antibiotic susceptibility tests aren't widely available in the world. Dual therapy with high-dose proton pump inhibitors reported to have higher eradication rates. Our objective was to determine eradication success and cost-effectivity of dual therapy in dyspeptic patients. Methodology: Patients were treated orally with either dual (n:74,omeprazole 20mg q.i.d and amoxicillin 1g b.i.d) or triple therapy (n:116,omeprazole 20mg b.i.d and amoxicillin 1g b.i.d and clarithromycin 500mg b.i.d) for 14 days. HpSA was requested 3 months later. The results were evaluated statistically, p values <0,05 were considered significant. Results: Patients (n:190) were included the study((80 female,110 male, mean age: 35.6 11yearr). Alcohol/smoking, endoscopic findings and H. pylon rates with pathological examinations were not significantly different between groups whereas there was significant difference in HpFast tests(p<0.01). Whe examined with HpSA tests 3 months after the treatment eradication rate was 81.1% in the dual therapy group versus 63.8% in the triple therapy group (p:0.011) Dual therapy was economic than triple therapy (144USDvs.107USD,p<0.001). Conclusions: Dual therapy seems more successful cost-effective and is less risky in terms of side effects compared to standard triple therapy in patients with dyspepsia.